Issue 7/2018
Content (13 Articles)
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?
Fernando Antoñanzas, Roberto Rodríguez-Ibeas, Carmelo A. Juárez-Castelló
Discounting in Economic Evaluations
Arthur E. Attema, Werner B. F. Brouwer, Karl Claxton
Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Matt Stevenson, Abdullah Pandor, Jean Hamilton, John Stevens, Clare Rowntree, Marrissa Martyn-St James, Andrew Rawdin, Ruth Wong
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Shijie Ren, Iñigo Bermejo, Emma Simpson, Ruth Wong, David L. Scott, Adam Young, Matt Stevenson
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
Alex Diamantopoulos, Emily Wright, Katerina Vlahopoulou, Laura Cornic, Nils Schoof, Toby M. Maher
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
Guy Neff, Woodie Zachry III
The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests
Alison F. Smith, Mike Messenger, Peter Hall, Claire Hulme
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
Irina A. Tikhonova, Nicola Huxley, Tristan Snowsill, Louise Crathorne, Jo Varley-Campbell, Mark Napier, Martin Hoyle
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Vanessa Buchanan, Will Sullivan, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday, Bruce Kirkham
Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”
Ena Singh
Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
Guy Neff, Woodie Zachry III